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Evaluation of variables associated with the patency of arte-
riovenous fistulas for hemodialysis created by a nephrologist
Avaliação de variáveis associadas à permeabilidade de fístulas 
arteriovenosas criadas por um nefrologista para fins de hemodiálise
Introdução: A fístula arteriovenosa (FAV) é 
considerada o acesso vascular padrão ouro 
para hemodiálise crônica, e sua falha pre-
diz taxas mais altas de morbimortalidade. 
Objetivos: 1) Avaliar a taxa de sucesso da 
FAV criada por um nefrologista e 2) identi-
ficar variáveis clínicas, laboratoriais e demo-
gráficas que influenciam a patência da FAV. 
Métodos: Estudo de coorte retrospectivo 
de 101 pacientes com doença renal crônica, 
totalizando 159 FAVs criados por um ne-
frologista entre junho de 2010 e junho de 
2013. Resultados: Das FAVs criadas, 124 
(78%) apresentaram patência imediata e 110 
(62,9%) apresentaram patência tardia. A he-
moglobina (10-12 g/dL) foi a única variável 
relacionada à patência tardia da FAV (p = 
0,05). A pressão arterial elevada no momento 
da cirurgia foi associada a um menor número 
de procedimentos por paciente (p = 0,001). A 
FAV proximal ocorreu com maior frequência 
em pacientes com dois acessos confecciona-
dos (p = 0,03). A taxa de sucesso da FAV foi 
semelhante à relatada anteriormente na lite-
ratura. Conclusão: O nível de hemoglobina 
no intervalo recomendado tem um impacto 
favorável na perviedade tardia da FAV e pres-
são arterial elevada durante a cirurgia no me-
nor número de acessos vasculares por pacien-
te. A alta taxa de sucesso indica que ela pode 
ser feita por nefrologistas treinados.
Resumo
Palavras-chave: Fístula Arteriovenosa; 
Diálise Renal; Insuficiência Renal Crôni-
ca; Grau de Desobstrução Vascular.
Introduction: Arteriovenous fistula (AVF) 
is considered the gold standard vascular 
access for chronic hemodialysis, and its 
failure predicts higher morbidity and mor-
tality rates. Objective: 1) To evaluate the 
success rate of AVF created by a nephrolo-
gist and 2) to identify clinical, laboratory, 
and demographic variables that influence 
AVF patency. Methods: A retrospective 
cohort study of 101 patients with chronic 
kidney disease for a total of 159 AVF cre-
ated by a nephrologist between June 2010 
and June 2013. Results: Of the AVFs cre-
ated, 124 (78%) displayed immediate pa-
tency and 110 (62.9%) displayed late pa-
tency. Hemoglobin (10-12 g/dL) was the 
only variable related to late AVF patency 
(p = 0.05). An elevated blood pressure at 
time of surgery was associated with a low-
er number of procedures per patient (p = 
0.001). Proximal AVF occurred more fre-
quently in patients with dual access (p = 
0.03). The AVF success rate was similar to 
those previously reported in the literature. 
Conclusion: Hemoglobin level in the rec-
ommended range has a favorable impact 
on late AVF patency and elevated blood 
pressure during surgery on the lower 
number of vascular accesses per patient. 
The high success rate indicates that it can 
be placed by trained nephrologists.
AbstRAct
Keywords: Arteriovenous Fistula; Renal 




Placement of the autogenous arteriove-
nous fistula (AVF) on the wrist as initially 
described in 19661 remains the vascular 
access of choice for the hemodialysis treat-
ment since it is associated with low levels 
of complications and better long-term du-
rability.2 In addition, the autogenous AVF 
is associated with a lower mortality rate in 
the first 6 months of hemodialysis compa-
red to the use of central venous catheters 
and vascular access with prosthesis.3 In 
2016 in Brazil, the prevalence of dialysis 
Braz. J. Nephrol. (J. Bras. Nefrol.) 2018;40(4):326-332
Evaluation of patency of arteriovenous fistulas created by a nephrologist for hemodialysis
327
patients using central venous catheter as vascular ac-
cess was 20.5%, and 2.2% were using prosthesis, me-
aning that 77.3% had autogenous AVF.4
AVF failure is an important clinical problem with 
high cost and morbidity in the treatment of patients 
with chronic kidney disease (CKD) stage 5 on hemo-
dialysis.5 The expenses with vascular access for hemo-
dialysis are high; for example, in 2007 in the United 
States, the Medicare expenditures for vascular access 
for dialysis were around US$1.8 billion.6 Vascular 
access failure for hemodialysis significantly increases 
morbidity rates and treatment costs,7 while function-
ing AVF are associated with lower mortality rates.8
In the United States, vascular access is created 
mainly by the vascular surgeon in contrast with that 
of other countries in which the nephrologist plans and 
creates the AVF.9 For example, in Italy and Japan, the 
rates of AVF placement by the nephrologist are 85% 
and 25%, respectively. In these countries, the time 
between the indication for and the creation of vas-
cular access is 5-6 days, much lower than the 40-43 
days observed in Canada and the United Kingdom, 
countries in which AVF are created by surgeons. As a 
result, this delay influenced the proportion of patients 
who started dialysis with an AVF.7
To date, no publication has reported on the ex-
perience of creating AVF by Brazilians nephrologists, 
thereby justifying the studies that assess this possibil-
ity as a strategy to reduce the use of central venous 
catheters at the start of dialysis. Thus, the objectives 
of this study were to evaluate the immediate and late 
patency rates of AVF created by a nephrologist and 
identify the demographic, clinical, and laboratory 
variables associated with vascular access functionality.
methodology
Sample and SettingS
This is a retrospective cohort study involving pa-
tients from the Pró Renal Centro de Nefrologia clinic, 
Barbacena, Minas Gerais, Brazil, on chronic hemodialy-
sis who provided consent for the construction of an AVF 
by a nephrologist (A.T.R.) who was previously trained to 
perform the procedure. Since there is no formal curricu-
lum in nephrology for the training of the creation of AVF, 
a fellowship training was took by the author (A.T.R.) 
with a vascular surgeon during a period of three months, 
when around 100 fistulas were made.
The evaluated period included the start of AVF 
creation by the nephrologist in June 2010 until June 
2013. Patients whose AVF were created by other med-
ical professionals not belonging to the service were 
not included in the study.
The variables assessed were present at the time 
of AVF placement since the same patient may have 
undergone more than one procedure. The informa-
tion was transcribed into a database that was spe-
cifically developed for the study and age, sex, and 
diagnosis of diabetes mellitus (DM) were record-
ed. We also analyzed the following variables: fre-
quencies of the procedures per period of grouped 
months, the anatomic area where the procedure 
was performed, total number of procedures per 
patient, presence or absence of high blood pressure 
(BP) (defined as BP > 140/90 mmHg) at the time 
of surgery, levels of intact parathyroid hormone 
(iPTH), phosphorus (P), and hemoglobin (Hb), 
and the product of calcium (Ca) × P. All of the 
laboratory data were collected in the month of the 
access placement. The iPTH values were stratified 
into three groups: < 500 pg/dL, 501-1000 pg/dL, 
and > 1000 pg/dL; the product of Ca × P was di-
vided into ≤ 55 and > 55; the level of P was divided 
into ≤ 5.5 mEq/L and > 5.5 mEq/L; the Hb values 
were stratified into ≤ 10 g/dL, 10.1-12.0 g/dL, and 
> 12 g/dL. The rate of complications related to the 
total number of procedures performed was also 
described.
The anatomical areas of the distal procedures were 
defined as those below the elbow fold with only one 
vascular anastomosis and using the radial or ulnar 
arteries and cephalic or basilic veins of the forearm, 
while those of the proximal procedures were defined 
as those in the region of the elbow fold with only one 
vascular anastomosis and using the brachial artery 
and basilic, cephalic, or brachial plexus veins.
Immediate patency was identified if the AVF pre-
sented thrill and/or palpable pulse and/or an audible 
murmur in the drainage vein in the immediate post-
operative period and late patency if the AVF could be 
punctured and used for a hemodialysis session 30-60 
days after the surgical procedure.
The study protocol was approved by the 
Committee for Ethics in Research of the Universidade 
Presidente Antônio Carlos - UNIPAC under protocol 
number 831/2010.
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stAtIstIcAl AnAlysIs
The data analysis was performed using the softwa-
re IBM SPSS Statistics for Macintosh, Version 21.0 
(Armonk, NY: IBM). The study variables correspon-
ded to those registered in the database mentioned 
above. The frequency and the averages, standard de-
viations, and percentages indicated for each variable 
were calculated. The patency rates of the fistulae with 
the other study variables were made in row by column 
contingency tables or analysis of variance (ANOVA) 
tables. The statistical significance of the differences 
obtained in the comparisons was determined using 
the chi-squared test or Fisher’s exact test for ANOVA 
tables. The dependent variables - immediate and late 
patency - were evaluated using logistic regression mo-
dels and adjusted for high BP at the time of the pro-
cedure, Hb level, and number of procedures per pa-
tient to obtain the odds ratio (OR), 95% confidence 
interval (CI 95%), and P value. The level of statistical 
significance for the analysis was 5%.
Results
We studied 101 patients (49 men [48.5%], 52 women 
[51.5%]; 38 [37.6%] with DM as a CKD cause or a 
comorbidity) with a mean age of 56.3 ± 16.2 years. 
Of the 159 AVFs, 54 (34%) were created between 
June 2010 and June 2011, 53 (33.3%) between July 
2011 and June 2012, and 52 (32.7%) between July 
2012 and June 2013. The AVFs were created once in 
100 patients (62.8%), twice in 38 (23.9%), and three 
or more times in 21 (13.2%). The maximum AVF 
per patient was five. An elevated BP was observed in 
92 (58.6%) surgeries. The distal site was used in 95 
(59,7%) procedures. Immediate and late AVF patency 
occurred in 124 (78.0%) and 110 (69.2%) procedu-
res, respectively.
Table 1 presents the clinical and laboratory vari-
ables during AVF placement with immediate patency. 
As can be observed, it was not influenced by gender, 
diabetic status, different periods of AVF placement, 
number of procedures per patient, anatomical area of 
the fistula, or iPTH and  P level. On the other hand, 
it is evident that the high BP, the product of Ca × P ≤ 
55, and Hb levels of 10.1-12.0 g/dL tend to favor im-
mediate AVF patency.
Table 2 shows the clinical and laboratory vari-
ables in relation to late AVF patency. An Hb level of 
10.1-12.0 g/dL was the only variable that positively 
impacted late AVF patency.
Tables 3 and 4 present the OR of the logistic re-
gression model adjusted for high BP at the time of 
surgery, number of procedures per patient (reference 
value equal to one procedure), and Hb (reference 
value, 10.1-12.0 g/dL); the dependent variables were 
immediate and late patency. There was a clear trend 
for high BP at time of AVF placement with immediate 
patency of the AVF (Table 3) and the positive impact 
of Hb levels of 10.1-12.0 g/dL in late patency.
Regarding the procedural complications, two pa-
tients (1.25%) had ruptured pseudoaneurysm, three 
AVF were associated with vascular access steal syn-
drome (1.88%), and one patient (0.62%) presented 
infection with good response to treatment with short-
spectrum antibiotics.
dIscussIon
Although our study was retrospective and carried out 
in a single center, which limits the generalizability of 
its results, its importance stems from being the first 
report of the experience of AVF created by a nephro-
logist in Brazil. The Brazilian renal replacement the-
rapy data indicate an increasing number of patients 
with functional renal failure in need of dialysis (more 
than doubled in the last decade) and that a signifi-
cant proportion of these patients start their treatment 
through temporary vascular access.4 Thus, our results 
in the Brazilian dialysis scenario are encouraging be-
cause they point to the possibility of nephrologists 
being empowered to construct AVF.
There is published evidence that the experience of 
the physician who creates AVF has a positive impact 
on its patency. For example, Fassiadis et al. observed 
an association between the experience of the surgeon 
that created the radiocephalic fistulae and the suc-
cess of the procedure.10 In our study, after dividing 
the construction of fistulas in three consecutive pe-
riods, we found that the AVF success rate was equal 
in the three periods and was not associated with the 
nephrologist’s surgical experience.
Blood pressure is an interesting aspect during AVF 
creation. In the dialysis clinic, it is not uncommon 
to observe AVF failure due to hypotensive episodes. 
A secondary analysis of the HEMO study6 demon-
strated, for the first time, an association among pre-
, intra- and post-dialytic hypotension and AVF loss. 
In our patients, high BP (> 140/90 mmHg) presented 
a protective effect in immediate AVF patency with a 
decreased need for new procedures per patient, but 
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this did not correlate with late patency. As described 
by Gandhi et al., elevated BP was not associated with 
complications and presented as a safe issue for the 
patient undergoing vascular access procedure.11 We 
did not specifically analyze the BP level but tabulated 
only whether the patient was hypertensive or not at 
the time of surgery as qualitative data and not for 
quantitative analysis. However, our opinion is that 
asymptomatic hypertensive patients should not be 
treated. In further studies, we aim to analyze which 
level of PA is more favorable in promoting better ac-
cess patency.
The non-uniformity of the distribution of sex in 
published studies limits the assessment of possible 
Characteristic With immediate patency Without immediate patency χ2/F p
N % N %
Sex
Male 59 47.6 19 54.3 0.491 0.567
Female 65 52.4 16 45.7
Diabetes mellitus
Yes 48 38.7 15 42.9 0.196 0.698
Not 76 61.3 20 57.1
Procedural period
June 2010 to June 2011 42 33.8 12 34.3 1.270 0.535
July 2011 to June 2012 39 31.5 14 40.0
July 2012 to June 2013 43 34.7 9 25.7
No. of procedures/patient
1 80 64.5 20 57.1 3.478a 0.182
2 31 25.0 7 20.0
≥ 3 13 10.5 8 22.9
Elevated BP in surgery
Yes 76 62.3 16 45.7 3.082 0.084
No 46 37.7 19 54.3
Place of access
Distal 75 62.0 20 58.8 0.112 0.842
Proximal 46 38.0 14 41.2
iPTH level
< 500 73 68.2 21 72.4 0.239a 0.948
501-1000 19 17.8 4 13.8
> 1000 15 14.0 4 13.8
Product of Ca × p
≤ 55 70 66.7 24 85.7 3.870 0.062
> 55 35 33.3 4 14.3
p
≤ 5.5 51 48.6 18 64.3 2.187 0.201
> 5.5 54 51.4 10 35.7
Hemoglobin
≤ 10.0 70 69.3 20 76.9 4.596a 0.087
10.1-12.0 24 23.8 2 7.7
> 12.0 7 6.9 4 15.4
χ2, Pearson’s chi-square; F, Fisher’s exact test (a); BP, blood pressure; iPTH, intact parathyroid hormone level; Ca, calcium level; P, phosphorus 
level.
tAble 1 characteriSticS inherent tO the fiStula prOcedureS that preSented Or nOt immediate    
 patency
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associations between sex and AVF patency. Although 
Wang et al. (2008)12 observed that their female pa-
tients had higher patency failure of the brachioce-
phalic fistulae, the AVF success rate was equal for the 
sexes, a result similar to ours.
The association between age and AVF patency 
remains controversial, with studies in favor9 and 
against,12 although elderly patients undergo hemo-
dialysis treatment through AVF less often.13 Among 
our patients, only 27% were elderly, which does not 
allow us to infer the impact of age on AVF patency.
Diabetes mellitus is admittedly a risk factor for 
endothelial disease and, thus, potentially favors the 
failure rate of AVF. However, in agreement with the 
Characteristic With late patency Without late patency χ2/F p
N % N %
Sex
Male 52 47.3 26 53.1 0.455 0.607
Female 58 52.7 23 46.9
Diabetes mellitus
Yes 44 40.0 19 38.8 0.021 1.000
No 66 60.0 30 61.2
Procedural period
June 2010 to June 2011 38 34.5 16 32.6 1.035 0.589
July 2011 to June 2012 34 30.9 19 38.8
July 2012 to June 2013 38 34.5 14 28.6
No. of procedures/patient
1 69 62.7 31 63.3 0.884 0.631
2 28 25.5 10 20.4
≥3 13 11.8 8 16.3
Elevated BP in surgery
Yes 67 62.0 25 51.0 1.686 0.131
No 41 38.0 24 49.0
Place of access
Distal 63 58.3 32 68.1 1.313 0.167
Proximal 45 41.7 15 31.9
iPTH (pcg/dL)
< 500 65 69.1 29 69.0 0.007 1.000
501-1000 16 17.1 7 16.7
> 1000 13 13.8 6 14.3
Product of Ca × P
≤ 55 65 69.1 29 74.4 0.361 0.677
> 55 29 30.9 10 25.6
P (mEq/L)
≤ 5.5 48 51.1 21 53.8 0.085 0.850
> 5.5 46 48.9 18 46.2
Hemoglobin (g/dL)
≤ 10.0 61 67.7 29 78.4 5.998 0.050
10.1-12.0 23 25.6 3 8.1
> 12.0 6 6.7 5 13.5
χ2, Pearson’s chi-square; F, Fisher’s exact test (*); BP, blood pressure; iPTH, intact parathyroid hormone level; Ca, calcium level; P, phosphorus 
level.
tAble 2 characteriSticS inherent tO the fiStula prOcedure that preSented Or nOt late patency
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findings of Kazemzadeh et al. (2008),14 we did not 
observe a negative impact of DM on AVF patency in 
our patients.
The guidelines on vascular access of the Kidney 
Disease Outcomes Quality Initiative (KDOQI) in 
patients with CKD on dialysis treatment15 recom-
mends distal AVF placement in the upper extremities 
to increase the possibility of creating new fistulae if 
needed. In our study, most AVF were placed distally 
(58.6%), while the ones placed proximally were as-
sociated with the need for more than one procedure.
The levels of iPTH and P as well as the product of 
Ca × P are associated with vascular changes such as 
calcification,16 atherosclerosis,17 and myointimal hy-
perplasia18 singly or in combination, and may nega-
tively impact AVF patency. In our patients, at the con-
struction of the AVF, the PTH, P, and Ca × P values 
were found within clinical limits recommended in the 
majority of the cases and did not influence the AVF 
patency outcome.
Recent studies performed in patients with non-
dialysis-dependent CKD, showed a generally nega-
tive impact of the correction of Hb levels to normal-
ity in the cardiovascular mortality.19,20 On the other 
hand, fewer studies have correlated AVF patency and 
Hb level, but one reported that the patients with Hb 
levels of 10.1-12.0 g/dL had the highest fistula paten-
cy rates.21 In our study, although records of Hb values 
were absent in approximately 20% of patients at the 
time of vascular access placement, the OR of late AVF 
patency was also higher if the Hb level was 10.1-12 g/
dL, while values < 10.0 g/dL and > 12 g/dL adversely 
affected venous access success.
As previously mentioned, in Brazil, the incidence 
and prevalence of patients who use the temporary 
central venous access for hemodialysis is unaccept-
ably high.4 There are several reasons to explain this 
unfortunate observation: 1) late referral of patients 
with advanced CKD to the nephrologist; 2) inade-
quate AVF funding; and 3) in most renal replacement 
therapy programs, AVF are placed by vascular sur-
geons who have little time away from their practices 
to create AVF in view of the growing number of new 
patients with the indication for hemodialysis. Thus, 
it is important to evaluate whether nephrologists can 
be empowered to construct AVF for their patients. 
The experiences reported in other countries suggest 
that this is possible. For example, Garcia-Trío et al. 
found no difference in patency rates of AVF placed 
by nephrologists and surgeons and reported a 21.8% 
primary failure rate.22 In our study, 78.0% of AVF 
presented criteria of immediate patency, very similar 
Variable Odds ratio p value 95% CI
Elevated BP in surgery 2.66 0.055 0.98-7.21
No. of procedures/patient
2 1.33 0.622 0.43-4.10
≥ 3 0.52 0.293 0.15-1.76
Hemoglobin (g/dL)
≤ 10.0 0.23 0.071 0.05-1.13
> 12.0 0.19 0.094 0.03-1.33
CI, confidence interval; BP, blood pressure.
tAble 3 reSultS Of the regreSSiOn mOdel applied tO the dependent variable Of immediate patency
Variable Odds ratio p value 95% CI
Elevated BP in surgery 1.45 0.396 0.61-3.45
No. of procedures/patient
2 1.63 0.332 0.61-4.34
≥ 3 0.85 0.790 0.27-2.72
Hemoglobin (g/dL)
≤ 10.0 0.25 0.035 0.07-0.90
> 12.0 0.17 0.043 0.03-0.94
CI, confidence interval; BP, blood pressure.
tAble 4 reSultS Of the regreSSiOn mOdel applied tO the dependent variable Of maintained late patency
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to these data. In addition, 69.2% of our patients had 
AFV with late patency, i.e., fistulae suitable for ve-
nous puncture, a percentage similar to that observed 
in other studies.23,24 These findings are of great impor-
tance because they indicate a new possibility in the 
approach to AVF, since the nephrologists can prepare 
and create the AVF for their patients and, therefore, 
shortening the time to venous access placement com-
pared to the long time still seen nowadays when the 
procedure is performed by surgeons.7 Also, it may 
become an important strategy to formalize a train-
ing curriculum within the scope of interventional ne-
phrology in order to increase this excellent field of ac-
tivity still not available to the Brazilian nephrologists.
Finally, it is important to emphasize the low rates 
of complications related to AVF in our patients. The 
percentage of complications observed is in accor-
dance with published data.25 No severe early or late 
complication, which could cause consequences or 
permanent damage to patients, was observed. This 
reflects the importance of a good surgical technique 
and the professional’s experience in the safe place-
ment of AVF, avoiding complications, and obtaining 
good final results.
In conclusion, this retrospective study on AVF 
placement by a Brazilian nephrologist indicated a 
late patency success rate similar to nephrologists 
and surgeons in other countries. In addition, high BP 
(> 140/90 mmHg) is important for the immediate pa-
tency of venous access, and Hb levels of 10.1-12.0 g/
dL is recommended to ensure late AVF patency.
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